BMJ Open  

Absolute cardiovascular risk scores and medication use in rural India: a cross-sectional study

Mulugeta Molla Birhanu 1, Roger G Evans, Ayse Zengin 1, Michaela Riddell, Kartik Kalyanram, Kamakshi Kartik, Oduru Suresh, Nihal Jacob Thomas, Velandai K Srikanth, Amanda G Thrift

ABSTRACT

Objectives We compared the performance of laboratory-based cardiovascular risk prediction tools in a low-income and middle-income country setting, and estimated the use of antihypertensive and lipid-lowering medications in those deemed at high risk of a cardiovascular event.

Design A cross-sectional study.

Setting The study population comprised adult residents (aged ≥18 years) of the Rishi Valley region located in Chittoor District, south-western Andhra Pradesh, India.

Participants 7935 participants were surveyed between 2012 and 2015. We computed the 10-year cardiovascular risk event (Framingham Risk Score (FRS), World Health Organization Risk Score (WHO-RS) and Australian Risk Score (ARS)), or a fatal cardiovascular event (Systematic COronary Risk Evaluation (SCORE)-high and SCORE-low).

Results Of participants aged 35–74 years, 3.5% had prior cardiovascular disease. The relationships between risk scores were quasi-linear with good agreement between the FRS and ARS (OLP slope=0.96, κw=0.89). However, the WHO-RS underestimated cardiovascular risk compared with all other tools. Twenty per cent of participants had ≥20% risk of an event using the ARS; 5% greater than the FRS and nearly threefold greater than the WHO-RS.

Similarly, 16% of participants had a risk score ≥5% using SCORE-high which was 6% greater than for SCORE-low. Overall, absolute cardiovascular risk increased with age and was greater in men than women. Only 9%–12% of those deemed ‘high risk’ were taking lipid-lowering or antihypertensive medication.

Conclusions Cardiovascular risk prediction tools perform disparately in this setting of disadvantage. Few deemed at high risk were receiving the recommended treatment.

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death globally. While communicable, maternal and nutritional diseases remain important causes of death in low-income and middle-income countries (LMICs), deaths from CVD are on the rise.

Indeed, approximately 80% of all deaths from CVD occur in LMICs. Therefore, an important strategy to tackle the growing burden of CVD in LMICs is promotion and expansion of CVD prevention strategies that have been successful in high-income countries (HICs).

In HICs, growth in the burden of CVD has been curbed through a strategy combining reduction in risk factors at the population level and by targeting high-risk groups. Various cardiovascular risk prediction tools have been developed which are now a core feature of many clinical guidelines. Tools commonly used in HICs include the Framingham Risk Score (FRS), the Australian Risk Score (ARS) and the Systematic COronary Risk Evaluation (SCORE) risk tools: SCORE-high and SCORE-low.

Critically, there are no well-validated tools for use in LMICs such as India. Furthermore, due to setting-dependent differences in both the prevalence and impact of various risk factors, the available tools may not be suitable in LMICs. The presence of multiple tools also creates uncertainty among policymakers and clinicians about which cardiovascular risk tool to choose for their setting.

To resolve this concern, the World Health Organization (WHO) recently developed multiple risk prediction tools in a low-income and middle-income country setting. The study was conducted using a large sample, standardised methods of data collection and comprehensive measures of cardiovascular risk factors. Due to the cross-sectional study design, we have not been able to fully resolve which risk prediction tool works best in this setting.
region-specific risk tools, but these have not been externally validated in disadvantaged settings such as rural India.

We hypothesised that cardiovascular risk prediction tools perform disparately in rural India, but regardless of which risk tool is used, medication use is inadequate in this disadvantaged population. Therefore, we first aimed to compare laboratory-based tools, to estimate 10-year CVD risk, among a cross-section of adults in a rural region of southern India. Our secondary aim was to estimate the use of antihypertensive and lipid-lowering medication in those deemed at high risk of a cardiovascular event by these tools.

METHODS

Study design

Cross-sectional.

Setting

The study population comprised adult residents (aged ≥18 years) of the Rishi Valley region located in the Chittoor District, south-western Andhra Pradesh, India (see online supplemental methods).

Participants

Following exclusion of one hamlet which comprised a wealthy school and four small hamlets with no residents, 216 hamlets were available for sampling. These were categorised into small, medium and large hamlets and a similar number of hamlets from each group were randomly sampled (online supplemental figure 1). Among the 133 hamlets sampled, there were 13,077 eligible residents, of whom 5,142 either refused or were otherwise unavailable for participation. This left 7,935 who participated in a baseline survey between August 2012 and December 2015. Among these, 6,472 had comprehensive data, while 1,463 had some data available (online supplemental figure 1). There were some differences in the characteristics of the two samples (see online supplemental methods and online supplemental table 1).

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Data collection techniques and procedures

Using standardised questionnaires, field-workers collected data on the following variables: (1) sociodemographic factors: age, sex, marital status, education and income; (2) lifestyle factors: smoking and alcohol consumption; (3) self-reported conditions: diabetes mellitus, hypertension, stroke, high cholesterol and cardiac disease; (4) standard clinical measures: blood pressure (BP), height and weight; and (5) lipid status: total cholesterol and high-density lipoprotein (HDL).

Arterial BP was measured in the seated position using a calibrated digital automatic BP monitor (OMRON HEM-907, OMRON Health-care, Kyoto, Japan), after 15 min at rest. Three measurements were taken at 3 min intervals using the appropriate cuff size, according to the WHO-STEPs protocol. Measurements continued until two consecutive readings differed by <10 mm Hg systolic and <6 mm Hg diastolic, with a maximum of 5 measurements. The mean of the last two consecutive measurements was considered the participant’s BP. Hypertension was defined as systolic BP (SBP)/diastolic BP ≥140/90 mm Hg and/or prescription of antihypertensive medication.

We measured height (within 0.1 cm) using a portable stadiometer (213, Seca, Hamburg, Germany) and weight (within 0.1 kg) using a portable digital weighting scale (9000SV3R, Salter, Kent, UK). Blood cholesterol concentration was measured using an Accutrend GCT device (Roche Diagnostics, Mannheim, Germany). Hypercholesterolaemia was defined as total cholesterol ≥214 mg/dL and/or prescription of lipid-lowering agents. Diabetes status was confirmed when participants self-reported having diabetes. Details of these measurements have been described previously.

Cardiovascular risk prediction tools

‘Absolute risk’ is a term used to describe the probability that an individual will have a cardiovascular event within a given time period. Risk prediction tools are variously referred to as risk tools, risk scores, risk equations, risk algorithms and risk functions. Herein, the term ‘tool’ refers to the specific algorithm used to generate an estimate of absolute risk, the term ‘score’ refers to the resulting estimate of absolute risk, and the term ‘band’ refers to absolute risk categories. We assessed absolute risk using five different risk prediction tools: the FRS, the ARS,1 the WHO Risk Score (WHO-RS),16 the SCORE-low and the SCORE-high.11 FRS, ARS and WHO-RS provide estimates for any cardiovascular event (fatal or non-fatal) whereas SCORE-low and SCORE-high predict a fatal cardiovascular event. For more details of the tools, see online supplemental methods, online supplemental figure 2 and online supplemental tables 2–4.

Calculation of cardiovascular risk score

The variables used to assess absolute risk included age, sex, smoking status, SBP, serum HDL, serum total cholesterol, and diabetes status. The individual-level risk scores were calculated using each of the five sex-specific risk tools. Then, for all people without a self-reported prior history of CVD (heart disease or coronary bypass surgery or angioplasty or stent inserted or stroke), the individual’s estimated 10-year absolute risk scores for a fatal or non-fatal cardiovascular event were categorised in risk bands (<10%, 10%–20% or ≥20%; see online supplemental methods). Similarly, the scores for a fatal cardiovascular event were categorised as <1%, 1%–5% or ≥5%.

Statistical analyses

Statistical analyses were performed in Stata V.15 (STATA IC/15, StataCorp) or SYSTAT (V.13). The WHO
cardiovascular risk package in Stata was used to estimate WHO-RS. A two-tailed \( p \leq 0.05 \) was considered statistically significant.

Frequencies within categorical variables are presented as percentages with 95% confidence intervals (95% CI). Mean and 95% CI were calculated for data that were distributed in an approximately normal fashion. We first assessed normality using the Shapiro-Wilk test and then manually inspected the distributions using histograms and Q-Q plots. Most variables failed the Shapiro-Wilk test, but visual inspection revealed that their distribution approximated normality. Dichotomous comparisons were made using the \( \chi^2 \) test for categorical variables and Student’s unpaired t-test for continuous variables.

Among participants without self-reported history of CVD, we estimated the distribution of risk scores across various age categories. The various risk tools are specific for people within various age ranges (online supplemental table 2 and online supplemental figure 2). To allow direct comparison of the scores between tools, we applied each tool to those aged 35–74 years in all instances. Moreover, for some of the participants (n=1463) some data were not available (online supplemental figure 1). Thus, we used complete case analysis to minimise bias and optimise precision. Ordinary least-products regression analysis was used to determine the relationships between the risk scores generated by the five risk prediction tools.

Because qualitative risk bands can be used to make clinical decisions, we also compared these across the various tools. Risk bands were classified based on the established cut-offs in various guidelines with a slight modification for the ARS. For example, in the ARS guidelines, the 5-year risk of a fatal or non-fatal cardiovascular event is categorised ‘high risk’ if the score is >15%. But, in our study, we applied a 10-year prediction horizon. Thus, to make the ARS cut-off comparable to the cut-offs for the FRS and WHO-RS, we considered ‘high risk’ when the score was ≥20% as has been suggested and used in prior studies. Similarly, for SCORE-high and SCORE-low, the 10-year risk of a fatal cardiovascular event was categorised ‘high risk’ if the score was ≥5%. Comparisons were made only among tools with the same endpoint (fatal event only (SCORE-high and SCORE-low) and fatal or non-fatal event (FRS, ARS, and WHO-RS)). The concordance level in pair-to-pair analyses of risk bands was assessed using quadratic weighted kappa (\( \kappa_w \)). Spearman’s rank correlation \( (r_s) \) was computed to assess the relationships between the various risk bands.

**RESULTS**

**Sociodemographic characteristics and disease status of participants**

Of the 7935 adults surveyed, 57% were women and the mean age was 44.9 years (SD ±16.2). In total, 3.5% of the participants had self-reported history of CVD, defined as self-reported heart disease (2%) or coronary bypass surgery (0.2%) or angiooplasty or stent inserted (0.4%) or stroke (1%) and 84% were aged between 35 and 74 years (online supplemental table 5). In subsequent analyses, participants were restricted to those without a self-reported history of CVD and aged between 35 and 74 years (n=4202). Compared with women (4%), men had a greater prevalence of diabetes (6.1%). Similarly, the prevalence of smoking was greater in men (35.9%) than in women (0.4%). But, the prevalence of hypercholesterolaemia and hypertension was similar in men and women (table 1). For qualitative risk band comparisons, only participants with complete data required for all tools were included (n=3444).

| Characteristics | Men n=1466 | 95% CI | Women n=1978 | 95% CI | P value |
|-----------------|-----------|--------|--------------|--------|---------|
| Age, years      | 51.8      | 51.2 to 52.3 | 50.5       | 50.0 to 51.0 | <0.001  |
| BMI, kg/m²      | 21.0      | 20.8 to 21.2 | 20.7       | 20.5 to 20.9 | 0.05    |
| Hypercholesterolaemia, n (%) | 178 (12.1) | 155 to 204 | 270 (13.7) | 241 to 301 | 0.19    |
| Hypertension, n (%) | 398 (27.1) | 365 to 432 | 493 (24.9) | 456 to 532 | 0.14    |
| Current smoker, n (%) | 527 (35.9) | 492 to 564 | 8 (0.4)    | 4 to 16     | <0.001  |
| Diabetes, n (%) | 89 (6.1)  | 73 to 109 | 80 (4.0)    | 64 to 99    | 0.01    |

Values are presented as mean (age, BMI) and frequency (%). P values for continuous variables were calculated according to independent sample t-test, while categorical variables were calculated using \( \chi^2 \).

Hypertension was defined as SBP/DBP ≥140/90 mm Hg and/or prescription of antihypertensive medication. Hypercholesterolaemia was defined as total cholesterol ≥214 mg/dL and/or prescription of lipid-lowering medication. Current smoker refers to use of any tobacco products such as bidis, cigarettes and cheroot. Diabetes refers to a self-report of the condition. BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Quantitative analysis of agreement between risk scores generated by the various risk tools

All relationships between risk tools were quasi-linear, with straight-line relationships explaining 64%–99% of the variance (figure 1, online supplemental table 6). The calculated regression equations allow approximate inter-conversion between each pair of scores. In all comparisons, the 95% confidence limits of the intercept of the regression equations did not include zero (online supplemental table 6). However, the divergence of the intercept from zero was relatively small, being the greatest for the comparison between WHO-RS and SCORE-high (−2.88%). In all comparisons, the 95% confidence limits of the slope did not include unity.

There was good agreement between the FRS and ARS in predicting the 10-year risk of a fatal or non-fatal cardiovascular event (slope=0.96). However, the WHO-RS systematically underestimated this risk compared with both the FRS (slope=0.37) and ARS (slope=0.39). The absolute 10-year risk of a fatal or non-fatal cardiovascular event determined by the WHO-RS tool more closely aligned with the 10-year risk of a fatal cardiovascular event determined by either SCORE-low (slope=0.69) or SCORE-high (slope=1.13) than with the FRS or ARS. SCORE-high systematically generated greater scores of absolute risk of a fatal cardiovascular event than SCORE-low (slope=1.62).

Qualitative analysis of agreement between risk bands generated by the various risk tools

In line with the observed quantitative relationships between the various risk scores, with regard to qualitative risk bands, there was good agreement between the FRS and ARS in predicting the 10-year risk of a fatal or non-fatal cardiovascular event, but poor agreement between the WHO-RS and both the FRS and ARS (table 2). The pairwise agreement between the WHO-RS and both the FRS and ARS was poor, particularly in those with high total cholesterol, high SBP, high body mass index or who had diabetes mellitus (online supplemental table 7). SCORE-high and SCORE-low showed good agreement in predicting the 10-year risk of a fatal cardiovascular event (percentage agreement=83.36; \( \kappa_w =0.84, r=0.86; \) table 2).

Agreement between the risk bands for the various tools was mostly greater for women than men, except for the comparison between the FRS and ARS (table 2 and online supplemental figure 3). In most cases, percentage agreement between scores declined with age, although this pattern was not evident for the quadratic weighted kappa (online supplemental figure 4).

Ten-year absolute risk of a cardiovascular event

The proportion of people categorised within each risk band differed for each of the five risk tools (table 3). For example, the proportion of individuals deemed at low risk
Open access

Birhanu MM, et al. BMJ Open 2022;12:e054617. doi:10.1136/bmjopen-2021-054617

In contrast, one-fifth of the participants were deemed at high risk (≥20% risk of fatal or non-fatal cardiovascular event) when using the ARS, 5% greater than that for the FRS and 12% greater than that for the WHO-RS. Across all risk prediction tools, the proportion of men deemed at high risk (≥20% risk of a fatal or non-fatal cardiovascular event or ≥5% risk of a fatal cardiovascular event) was greater than for women (table 3).

The proportion of participants deemed at high risk of a fatal or non-fatal cardiovascular event were progressively greater with age (figure 2, online supplemental table 8). Among those aged 35–54 years, less than 2.0% were in the high-risk category (≥5% risk) for a fatal cardiovascular event using the SCORE-high or SCORE-low. In addition, when using the ARS, 5% of participants were deemed at high risk (≥20%) of a fatal or non-fatal cardiovascular event, nearly 2% greater than that for the FRS and WHO-RS. In all risk prediction tools, across all age groups, more men were in the high-risk category than women (figure 2, online supplemental table 8).

Antihypertensive and lipid-lowering medications

Among the 189 individuals aged 35–74 years with self-reported history of CVD, over one third were taking either antihypertensive or lipid-lowering medications (online supplemental figure 5). More details are provided in online supplemental results and online supplemental table 9.

Of those without self-reported history of CVD but at high risk of a cardiovascular event, 9%–12% of individuals reported taking either antihypertensive or lipid-lowering therapy, and this was similar between risk prediction tools (table 4). Among the 189 individuals aged 35–74 years with self-reported history of CVD, over one third were taking either antihypertensive or lipid-lowering medications (online supplemental figure 5). More details are provided in online supplemental results and online supplemental table 9.

Among those aged 35–74 years with self-reported history of CVD, over one third were taking either antihypertensive or lipid-lowering therapy, and this was similar between risk prediction tools (table 4). When limiting this analysis to those with a diagnosis of hypertension or hypercholesterolaemia, between 10% and 17% of those categorised as being at high risk were taking either antihypertensive or lipid-lowering medication (online supplemental figure 5). More details are provided in online supplemental results and online supplemental table 9.

Among those aged 35–74 years with a diagnosis of hypertension or hypercholesterolaemia, between 10% and 17% of those categorised as being at high risk were taking either antihypertensive or lipid-lowering medication (online supplemental figure 5). More details are provided in online supplemental results and online supplemental table 9.

DISCUSSION

Our analysis provides two novel and important findings. First, we found that cardiovascular risk prediction tools performed disparately in a resource-constrained rural setting in a LMIC. Thus, only some, but not all, are likely valid in such settings. Thus, relative merits can only be assessed by prospective follow-up, which is currently underway. Our other important finding was that cardiovascular risk prediction tools performed disparately in a resource-constrained rural setting in a LMIC. Thus, only some, but not all, are likely valid in such settings. Thus, relative merits can only be assessed by prospective follow-up, which is currently underway. Our other important finding was that

Table 2 Concordance between categories* of absolute risk in cardiovascular risk prediction tools among adults without self-reported history of cardiovascular disease at baseline and aged 35–74 years

| Comparison of cardiovascular risk prediction tools | Men (n=1466) | Women (n=1978) | Total (n=3444) |
|---------------------------------------------------|-------------|----------------|---------------|
|                                                   | Agreement (%) | Quadratic weighted kappa | Spearman’s r (r_s) | Agreement (%) | Quadratic weighted kappa | Spearman’s r (r_s) | Agreement (%) | Quadratic weighted kappa | Spearman’s r (r_s) |
| FRX versus ARS                                     | 91.81       | 0.94            | 0.95          | 84.13       | 0.76            | 0.77          | 87.40       | 0.89            | 0.89             |
| FRX versus WHO-RS                                  | 52.93       | 0.48            | 0.66          | 86.70       | 0.70            | 0.70          | 72.33       | 0.58            | 0.65             |
| ARS versus WHO-RS                                  | 49.59       | 0.44            | 0.64          | 76.29       | 0.60            | 0.59          | 64.92       | 0.52            | 0.63             |
| SCORE-low versus SCORE-high                        | 74.28       | 0.80            | 0.85          | 90.09       | 0.86            | 0.85          | 83.36       | 0.84            | 0.86             |

Agreement was measured by using risk bands generated by the various risk tools.

*The category of risk bands are: <10%, 10% to <20%, or ≥20% risk for FRX, ARS and WHO-RS and <1%, 1% to <5%, or ≥5% risk for SCORE-high and SCORE-low.

ARS, Australian Risk Score; FRX, Framingham Risk Score; high, regions of high cardiovascular risk; low, regions of low cardiovascular risk; r_s, Spearman’s r; SCORE, Systematic COronary Risk Evaluation; WHO-RS, WHO Risk Score.
event or ≥5% risk of a fatal event) were receiving antihypertensive or lipid-lowering therapy. Thus, there remains a considerable treatment-gap in those at risk of a cardiovascular event in this setting.

Performance of the risk prediction tools

We found substantial variation in the absolute cardiovascular risk estimates of various risk prediction tools, as has been reported by others. The lack of well-developed and validated risk prediction tools in LMICs and the presence of multiple tools with varied predictive performance creates a lack of certainty regarding which tool to choose in clinical practice in settings of disadvantage in LMICs. Notably, the current WHO-RS showed lower estimated absolute risk levels and moderate agreement compared with the ARS and FRS which is consistent with findings based on the previous version of this risk prediction tool. While risk prediction tools have the potential to identify those at high risk of a cardiovascular event in LMICs, the disparities in categorisation likely mean that some are invalid in such a setting. Prospective follow-up will enable assessment of their validity.

Gender and age

Predicted risk of a fatal or non-fatal cardiovascular event in rural south India was greater in men than women. This observation is consistent with prior work in both LMICs and HICs. It likely reflects the better risk factor profile in women than men, such as lesser prevalence of diabetes and tobacco use. In accordance with our findings, another plausible explanation could be use of antihypertensive or lipid-lowering treatments which is greater in women than men. Previous investigators have also suggested that this could be biological and related to sex hormones.

Fatal or non-fatal cardiovascular events have been reported to occur at younger ages in an LMIC setting than in an HIC setting. Our finding that only 3%–5% of the participants aged 35–54 years were deemed at high risk of a fatal or non-fatal cardiovascular event does not really accord with this prior finding, so potentially these risk tools may underestimate risk in these settings. Thus, it may be beneficial to target primary prevention strategies to those of a younger age. Such strategies could include screening for risk factors and assessment of cardiovascular risk, counselling and treatment. Indeed, in a recent consensus statement for Aboriginal and Torres Strait Islander populations in Australia, a significantly disadvantaged community, it was recommended that cardiovascular risk assessment commences at the age of 18 years, and at 30 years at the

| Table 3 | Category of 10-year risk bands of a cardiovascular event among adults without a self-reported history of cardiovascular disease at baseline and aged 35–74 years |
|------------------------|---------------------------------|---------------------------------|
| Risk prediction tools and risk bands | Men (n=1466) | Women (n=1978) | Total (n=3444) |
| FRS | | |
| <10% | 665 (45.4) | 1635 (82.7) | 2300 (66.8) |
| 10%–20% | 364 (24.8) | 250 (12.6) | 614 (17.8) |
| ≥20% | 437 (29.8) | 93 (4.7) | 530 (15.4) |
| ARS | | |
| <10% | 610 (41.6) | 1411 (71.3) | 2021 (58.7) |
| 10%–20% | 357 (24.4) | 378 (19.1) | 735 (21.3) |
| ≥20% | 499 (34.0) | 189 (9.6) | 688 (20.0) |
| WHO-RS | | |
| <10% | 1104 (75.3) | 1757 (88.8) | 2861 (83.1) |
| 10%–20% | 231 (15.8) | 84 (4.3) | 315 (9.2) |
| ≥20% | 131 (8.9) | 137 (6.9) | 268 (7.8) |
| SCORE-low | | |
| <1% | 761 (51.9) | 1481 (74.9) | 2242 (65.1) |
| 1%–5% | 457 (31.2) | 417 (21.1) | 874 (25.4) |
| ≥5% | 248 (16.9) | 80 (4.0) | 328 (9.5) |
| SCORE-high | | |
| <1% | 546 (37.2) | 1335 (67.5) | 1881 (54.6) |
| 1%–5% | 510 (34.8) | 513 (21.1) | 1023 (29.7) |
| ≥5% | 410 (28.0) | 130 (6.6) | 540 (15.7) |

All values are reported as frequencies (percentages). Due to rounding, percentages may not add up to 100%.

ARS, Australian Risk Score; FRS, Framingham Risk Score; high, regions of high cardiovascular risk; low, regions of low cardiovascular risk; SCORE, Systematic COronary Risk Evaluation; WHO-RS, WHO Risk Score.
countries according to economic status. For example, it has been estimated that over 80% of eligible patients from low-income countries, 45% in upper-middle-income countries, and 11% in HICs do not receive their recommended treatment. Affordability of medications makes a major contribution to these discrepancies. In India, for example, 65% of households could not afford the monthly cost (US$30) of the two lowest cost antihypertensives plus the lowest cost statin medication. Some of the treatment-gap in LMICs is probably a consequence of lack of awareness. Indeed, approximately 60% of those with hypertension were unaware of their hypertensive status and about a quarter had never previously had their BP measured. These observations may indicate missed opportunities for diagnosis of hypertension or missed opportunities for educating the patient about their BP and treatment options. Thus, enhanced screening, together with education about hypertension, should go some way to improving uptake of medications. But, other factors such as under-diagnosis, limited access to healthcare, lack of prescription, contraindications, cost, resistance/refusal by the patient and cultural beliefs are likely also important. Use of cardiovascular risk prediction tools, to manage primary prevention, that are relevant to the population, may help overcome at least one of these barriers, as they enable strategies that are more cost-effective and efficient than targeting single risk factors. Facilitating treatment in those at high risk of CVD may help avert the vicious cycle of poverty and non-communicable diseases in LMICs. For people identified as being at high risk of a cardiovascular event, national and international guidelines recommend various lifestyle behaviour changes alone or in combination with pharmacotherapy. However, given the difference in the risk performance of the risk prediction tools, in our study region and similar LMICs, well-validated tools with appropriate cut-offs are required to better target high-risk groups for early prevention and treatment in LMICs.

Strengths and limitations

To the best of our knowledge, ours is the first comprehensive assessment of multiple risk prediction tools and use of medications in a large sample in a rural LMIC setting. We used rigorous training of all data collectors and research staff to ensure standardisation of methods for data collection, validity and generalisability of our findings. In addition, we used comprehensive measures of cardiovascular risk factors. Our community-based findings provide evidence for policy-makers and clinicians for optimising prevention at the population level and for treatment at an individual level.

A limitation of our study was the large proportion of people who refused to participate. However, the socio-demographics of the screened participants were similar to those of participants included in the analysis, so this
CONCLUSIONS

In a disadvantaged rural setting in a LMIC, cardiovascular risk prediction tools performed disparately, resulting in uncertainties regarding the best choice of tool for this setting. Our findings indicate that absolute cardiovascular risk is higher in men than women and increases markedly with age. These laboratory-based tools have the potential to help identify individuals at high risk of a cardiovascular event in such settings. But, first, their validity must be established using hard outcomes. Importantly, few individuals deemed at high risk were receiving antihypertensive or lipid-lowering therapy. Thus, there remains a considerable treatment gap in those at risk of a cardiovascular event in this setting.

Author affiliations
1Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, Victoria, Australia
2Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Clayton, Victoria, Australia
3Rishi Valley Rural Health Centre, Chittoor District, Andhra Pradesh, India
4Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India
5Peninsula Clinical School, Central Clinical School, Monash University, Frankston, Victoria, Australia

may not have reduced the generalisability of our findings. In addition, we were unable to fully resolve which risk prediction tool works best in our setting. Further prospective data are required to answer this question.
Acknowledgements We gratefully acknowledge the healthcare workers and study staff who undertook the field-work and collected the data for this study.

Contributors MMB, RGE and AGT contributed to the conception or design, analysis and interpretation of data for the work. AGT, RGE, MR and OS contributed to the acquisition of data. AGT is the guarantor and accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. MMB, RGE, AZ, MR, KkaJ, KkaR, DS, NJT, VKS and AGT contributed to interpretation of the findings. MMB and AZ drafted the manuscript. All authors critically revised and provided intellectual input to the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Funding This work was supported by the National Health and Medical Research Council of Australia (grant numbers 1005740, 1040030 and 1042600). MMB is supported by Monash Graduate Scholarships.

Competing interests Professor Thrift reports grants from the National Health and Medical Research Council of Australia (GNT1042600, GNT1005740, GNT1040030, GNT1122455, GNT1171966, GNT1143355, and GNT1182017), Stroke Foundation Australia (SG1807), and Heart Foundation, Australia (VG102282) for this study and for other projects outside the submitted work.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Ethical approval was obtained from the Rishi Valley Education Centre (RVEC), the Health Ministry’s Screening Committee of the Indian Council of Medical Research (58/4/11F/CHR/2013/NCD II), and Monash University (CF13/2516-2013001327). After explaining the purpose of the study, field workers sought informed consent from each study participant. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The Rishi Valley Study is an ongoing cohort among disadvantaged communities in rural India. We have a successful history of conducting collaborative research and we welcome specific proposals for new collaborations. Deidentified and restricted data are available on reasonable request. Initial enquiries should be made to the principal investigator AGT (Amanda.Thrift@monash.edu).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Mulugeta Molla Birhanu http://orcid.org/0000-0003-0364-279X Ayse Zengin http://orcid.org/0000-0001-6428-6165 Amanda G Thrift http://orcid.org/0000-0001-8533-4170

REFERENCES

1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021.

2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 185 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1736–88.

3. World Health Organization. Projections of Mortality and Causes of Death, 2016 to 2060. Available: https://www.who.int/healthinfo/global_burden_disease/GHE_DthWBInc_Proj_2016-2060.xlsx?ua=1 [Accessed 28 Jan 2021].

4. Prabhakaran D, Joonpr P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation 2016;133:1605–20.

5. Zhao D, Liu J, Xie W, et al. Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol 2015;12:301–11.

6. Bonis R, Magnusson J, Howard P, et al. Country actions to meet uncommitments on non-communicable diseases: a stepwise approach. Lancet 2013;381:575–84.

7. National Vascular Disease Prevention Alliance (NVDPA). Guidelines for the Management of Absolute Cardiovascular Disease Risk, 2012. Available: https://www.cvdcheck.org.au/australian-absolute-cardiovascular-disease-risk-calculator [Accessed 19 Jan 2021].

8. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–61.

9. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2395–59.

10. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008;117:743–53.

11. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.

12. Damen JAAG, Hoorn LJ, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 2016;353:i2416.

13. Ministry of Health and Family Welfare. National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke, GOI. Government of India, 2017. https://main.mohfw.gov.in/Major-Programmes/non-communnicable-diseases-injury-trauma/Non-Communicable-Disease-II/Non-Programme-for-Prevention-and-Control-of-Cancer-Diabetes-Cardiovascular-diseases-and-Stroke-NPCDCS

14. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.

15. Singh T, Pilania M, Jat GS, et al. Ambiguity about selection of cardiovascular risk stratification tools: evidence from a North Indian rural population. India J Community Med 2013;38:170–4.

16. WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019;7:e1332–45.

17. World Health Organization. WHO STEPS: Surveillance Manual: the WHO STEPSwise Approach to Non-communicable Disease Risk Factor Surveillance. Geneva: World Health Organization, 2017. https://www.who.int/nccs/surveillance/steps/STEPS_Manual.pdf

18. Thrift AG, Ragavan RS, Riddell MA, et al. Hypertension in rural India: the contribution of socioeconomic position. J Am Heart Assoc 2020;9:e01486.

19. Gamage DG, Riddell MA, Joshi R, et al. Effectiveness of a scalable group-based education and monitoring program, delivered by health workers, to improve control of hypertension in rural India: a cluster randomised controlled trial. PLoS Med 2020;17:e1002997.

20. Riddell MA, Joshi R, Oldenburg B, et al. Cluster randomised feasibility trial to improve the control of hypertension in rural India (CHIRI): a study protocol. BMJ Open 2016;6:e012404.

21. Kaptose S, Pennells L, World Health organization (WHO) CVD risk score UK, University of Cambiride, 2019. http://www.phpc.cam.ac.uk/ceu/erfc/programs/

22. Hughes RA, Heron J, Sterne JAC, et al. Accounting for missing data in statistical analyses: multiple imputation is not always the answer. Int J Epidemiol 2019;48:1294–304.

23. Ludbrook J. Comparing methods of measurements. Clin Exp Pharmacol Physiol 1997;24:193–203.

24. World Health Organization. HEARTS Technical Package: Risk-based CVD Management, 2020. Available: https://www.who.int/cardiovascular_diseases/heart/en/ [Accessed 20 Jan 2021].

25. Aronson CI, Katzarovsky PY, Gossen I, et al. Revised Adult Treatment Panel III guidelines and cardiovascular disease mortality in men attending a preventive medical clinic. Circulation 2005;112:1478–85.
Open access

26 Albarqouni L, Doust JA, Magliano D, et al. External validation and comparison of four cardiovascular risk prediction models with data from the Australian diabetes, obesity and lifestyle study. Med J Aust 2019;210:161–7.

27 Doust JA, Banner C, Bell KJL. Future directions in cardiovascular disease risk prediction. Aust J Gen Pract 2020;49:488–94.

28 Ludbrook J. Statistical techniques for comparing measurers and methods of measurement: a critical review. Clin Exp Pharmacol Physiol 2002;29:527–36.

29 Sim J, Wright CC. Test-kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85:257–68.

30 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74.

31 Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 2012;24:69–71.

32 Calabria B, Korda RJ, Lovett RW, et al. Absolute cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians. Med J Aust 2018;209:35–41.

33 Gaziano TA, Pandya A, Steyn K, et al. Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. BMC Med 2013;11:170.

34 Selvarajah S, Kaur G, Haniff J, et al. Comparison of the Framingham risk score, score and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol 2014;176:211–8.

35 Otgontuya D, Oum S, Buckley BS, et al. Assessment of total cardiovascular risk using WHO/ISH risk prediction charts in three low and middle income countries in Asia. BMC Public Health 2013;13:539.

36 Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia. Med J Aust 2016;204:320.

37 Walli-Attaei M, Joseph P, Rosengren A, et al. Cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians: a prospective epidemiological survey. Lancet 2011;378:1231–43.

38 Attai MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE Study data. Lancet Public Health 2017;2:e11–9.

39 Mohanty SK, Upadhyay AK, Shekhar P, et al. Missed opportunities for hypertension screening: a cross-sectional study, India. Bull World Health Organ 2022;100:30–9.

40 Busingye D, Arabshahi S, Evans RG, et al. Factors associated with awareness, treatment and control of hypertension in a disadvantaged rural Indian population. J Hum Hypertens 2017;31:347–53.

41 Ragavan RS, Joshi R, Evans RG, et al. Additive association of knowledge and awareness on control of hypertension: a cross-sectional survey in rural India. J Hypertens 2021;39:107–16.

42 Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–68.

43 Bhatia M, Kumar M, Dixit P, et al. Diagnosis and treatment of hypertension among people aged 45 years and over in India: a sub-national analysis of the variation in performance of Indian states. Front Public Health 2021;9:766458.

44 Roy A, Praveen PA, Amarchand R, et al. Changes in hypertension prevalence, awareness, treatment and control rates over 20 years in national capital region of India: results from a repeat cross-sectional study. BMJ Open 2017;7:e015638.

45 Praveen D, Peiris D, MacMahon S, et al. Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India. BMC Public Health 2018;18:1264.

46 Karmali KN, Lloyd-Jones DM, van der Leeuw J, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. PLoS Med 2018;15:e1002538.

47 Bertram MY, Sweeney K, Lauer JA, et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet 2018:391:2071–8.

48 Niessen LW, Mohan D, Akukwe JK, et al. Tackling socioeconomic inequalities and non-communicable diseases in low-income and middle-income countries under the sustainable development agenda. Lancet 2018;391:2036–46.